BiotechTube
Catapult Therapeutics

Catapult Therapeutics

Leiden, Netherlands· Est.
catapult-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $44.5M

Overview

Catapult Therapeutics is a Dutch-Spanish biotech advancing CAP-100, a first-in-class anti-CCR7 antibody for hematological cancers. Its lead program is in Phase 1 for relapsed/refractory CLL/SLL, with a mechanism that blocks tumor cell migration to lymph nodes and induces cell killing. The company leverages proprietary antibody generation technology from Pepscan and is led by a cross-border team of experienced managers and scientists.

OncologyHematology

Technology Platform

Specialized capability to generate antibodies against the challenging GPCR target CCR7, enabled by Pepscan's proprietary antibody generation technology. Focus on a dual MOA: blocking CCR7-mediated tumor cell migration/survival and inducing ADCC.

Funding History

4
Total raised:$44.5M
Series A$16M
Series A$20M
Seed$3.5M
Seed$5M

Opportunities

CAP-100's unique mechanism targeting lymph node homing addresses an unmet need in relapsed/refractory CLL and could be complementary to existing therapies, enabling combination regimens.
The target's expression across multiple hematological malignancies and in GvHD offers significant pipeline expansion potential from a single asset.

Risk Factors

High clinical risk as a first-in-class agent targeting a novel pathway; failure in Phase 1 would be catastrophic.
Financial vulnerability as a private, single-asset company reliant on raising capital.
Navigating a competitive CLL market to demonstrate differentiated efficacy.

Competitive Landscape

The competitive landscape in CLL is dominated by BTK inhibitors (e.g., ibrutinib, acalabrutinib) and BCL-2 inhibitors (venetoclax). CAP-100 is differentiated by its unique CCR7 mechanism, not directly competing with these agents on the same target. It faces competition from other novel modalities in development for late-line CLL. Its true competition is the high bar for efficacy and safety set by existing standards of care.

More companies in Biologics / Biosimilars →More companies in Netherlands →